Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (ResQ108B-PANC)
Sponsor: ImmunityBio, Inc.
Listed as NCT07488884, this observational or N/A phase trial focuses on Pancreatic Cancer and Pancreatic Cancer Resectable and remains actively recruiting participants. Sponsored by ImmunityBio, Inc., it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recordedEligibility Summary
This is an open-label, phase 1 clinical trial to evaluate the safety and preliminary efficacy of neoadjuvant chemoimmunotherapy (NAI, sotevtamab, and zabadinostat in combination with gemcitabine and nab-paclitaxel) followed by resection and adjuvant immunotherapy for participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Eligible participants will undergo endoscopic ultrasound (EUS)-guided biopsies of the primary pancreatic tumor within 7 days of enrollment and prior to study day 1. EUS-guided biopsies will be used for histopathological examination to give clinical diagnostic information (as SoC) and will be stored in an ethically approved tissue bank.
Contact Information
- ImmunityBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.